The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

FURTHER EXPERIENCES OF THE USE OF MALONONITRILE IN THE TREATMENT OF MENTAL ILLNESSES

Published Online:https://doi.org/10.1176/ajp.107.2.95

1. The present paper offers some comments on the preliminary report by MacKinnion, Hoch, Cammer, and Waelsch on the treatment of mental illnesses with malononitrile. The forementioned authors reported 9 cases and stated that they obtained negative results. Their negative results are correlated by the writer to the short duration of the individual treatments.

To this extent, the results of MacKinnon et al. confirm the experience of the writer (Hydén and Hartelius 1948). No therapeutic effects have been observed to follow an m-treatment with a duration of only 15 minutes. In order to obtain results, emphasis is placed here—as in the earlier report (1948)—on the importance of a sufficiently long duration of the individual treatment.

2. The writer also reports on a more recent series of 40 patients with recorded katamneses.

3. Each patient was given an average of 1,250 mg. The average individual dose was 2.4 mg/kg body weight. The average dura-of the m-stage was 48 minutes. The average number of treatments in a course was 8.

4. Table 1 shows the distribution of the cases according to the diagnoses. Endogenous depressions predominate.

5. The mental effect is in the nature of a stimulation that becomes evident within 24-48 hours of each treatment.

6. The results are collocated in Table 2. They are markedly positive in 23 cases, relatively positive in 9, and negative in 8. The results are lasting in 22 cases and transient in 10.

7. The relation between malononitrile treatment and ECT and other forms of therapy is discussed. Twenty-six patients received ECT before malononitrile treatment, with varying results. Contraindications to ECT were present in 23 cases.

8. The clinical value of the method is due mainly to the positive results, its freedom

from risks, and the fact that it is less limited than ECT by contraindications.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.